Symbols / MIST Stock $1.37 -3.77% Milestone Pharmaceuticals Inc.
MIST (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteMilestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-14 | main | Wells Fargo | Overweight → Overweight | $7 |
| 2026-01-06 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-12-16 | main | Wells Fargo | Overweight → Overweight | $8 |
| 2025-12-15 | up | TD Cowen | Hold → Buy | $8 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-09-11 | init | Wells Fargo | — → Overweight | $4 |
| 2025-04-01 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-10-14 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-08-22 | init | Rodman & Renshaw | — → Buy | $9 |
| 2024-07-01 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2024-03-05 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2024-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
- Biotech Milestone pairs May 13 results with investor webcast - Stock Titan Wed, 06 May 2026 07
- $MIST stock is down 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 13 May 2026 07
- Should I buy Milestone Pharmaceuticals (MIST) - Zacks Investment Research Wed, 13 May 2026 07
- Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance Fri, 15 May 2026 07
- Heart-rhythm nasal spray fills around 600 scripts as Phase 3 starts - Stock Titan Wed, 13 May 2026 07
- Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 13 May 2026 07
- What date does Milestone Pharmaceuticals's (MIST) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research Wed, 13 May 2026 07
- [EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan ue, 26 May 2026 10
- Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST) - Yahoo Finance Wed, 13 May 2026 07
- $MIST stock is up 10% today. Here's what we see in our data. | MIST Stock News - Quiver Quantitative Wed, 08 Apr 2026 07
- NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19 - Stock Titan hu, 14 May 2026 07
- Three new hires get 123,000 Milestone stock options under Nasdaq rule - Stock Titan hu, 02 Apr 2026 07
- Adage (MIST) holds 8,000,000 warrant-derived shares, 6.37% - Stock Titan Wed, 13 May 2026 07
- Milestone (Nasdaq: MIST) posts Q1 loss as first CARDAMYST sales begin - Stock Titan Wed, 13 May 2026 07
- RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan Fri, 15 May 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.55
|
0.00
-100.00%
|
1.00
-80.00%
|
5.00
|
| Operating Revenue |
|
1.55
|
0.00
-100.00%
|
1.00
-80.00%
|
5.00
|
| Operating Expense |
|
63.69
+51.27%
|
42.10
-32.20%
|
62.10
-3.94%
|
64.64
|
| Research And Development |
|
18.11
+26.13%
|
14.36
-53.76%
|
31.05
-22.04%
|
39.83
|
| Selling General And Administration |
|
45.58
+64.27%
|
27.75
-10.63%
|
31.05
+25.12%
|
24.81
|
| Selling And Marketing Expense |
|
28.30
+157.24%
|
11.00
-27.20%
|
15.11
+66.18%
|
9.10
|
| General And Administrative Expense |
|
17.27
+3.18%
|
16.74
+5.08%
|
15.93
+1.36%
|
15.72
|
| Other Gand A |
|
17.27
+3.18%
|
16.74
+5.08%
|
15.93
+1.36%
|
15.72
|
| Total Expenses |
|
63.69
+51.27%
|
42.10
-32.20%
|
62.10
-3.94%
|
64.64
|
| Operating Income |
|
-62.14
-47.59%
|
-42.10
+31.09%
|
-61.10
-2.44%
|
-59.64
|
| Total Operating Income As Reported |
|
-62.14
-47.59%
|
-42.10
+31.09%
|
-61.10
-2.44%
|
-59.64
|
| EBITDA |
|
-59.11
-56.23%
|
-37.83
+33.67%
|
-57.04
+2.16%
|
-58.30
|
| Normalized EBITDA |
|
-59.11
-56.23%
|
-37.83
+33.67%
|
-57.04
+2.16%
|
-58.30
|
| Reconciled Depreciation |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| EBIT |
|
-59.22
-56.10%
|
-37.94
+33.59%
|
-57.13
+2.15%
|
-58.39
|
| Net Income |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Pretax Income |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Non Operating Interest Income Expense |
|
-0.92
-257.46%
|
0.58
-58.74%
|
1.41
+12.68%
|
1.25
|
| Interest Expense Non Operating |
|
3.84
+7.18%
|
3.58
+40.21%
|
2.55
|
0.00
|
| Net Interest Income |
|
-0.92
-257.46%
|
0.58
-58.74%
|
1.41
+12.68%
|
1.25
|
| Interest Expense |
|
3.84
+7.18%
|
3.58
+40.21%
|
2.55
|
0.00
|
| Interest Income Non Operating |
|
2.92
-29.88%
|
4.16
+4.97%
|
3.97
+216.35%
|
1.25
|
| Interest Income |
|
2.92
-29.88%
|
4.16
+4.97%
|
3.97
+216.35%
|
1.25
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income From Continuing Operation Net Minority Interest |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income From Continuing And Discontinued Operation |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income Continuous Operations |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Normalized Income |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Net Income Common Stockholders |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Diluted EPS |
|
—
|
-0.67
+51.80%
|
-1.39
-0.72%
|
-1.38
|
| Basic EPS |
|
—
|
-0.67
+51.80%
|
-1.39
-0.72%
|
-1.38
|
| Basic Average Shares |
|
—
|
62.21
+44.82%
|
42.96
+1.19%
|
42.45
|
| Diluted Average Shares |
|
—
|
62.21
+44.82%
|
42.96
+1.19%
|
42.45
|
| Diluted NI Availto Com Stockholders |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
75.23
|
| Current Assets |
|
73.03
|
| Cash Cash Equivalents And Short Term Investments |
|
66.00
|
| Cash And Cash Equivalents |
|
13.76
|
| Other Short Term Investments |
|
52.24
|
| Receivables |
|
3.85
|
| Other Receivables |
|
2.42
|
| Taxes Receivable |
|
0.91
|
| Accrued Interest Receivable |
|
0.53
|
| Inventory |
|
—
|
| Prepaid Assets |
|
3.18
|
| Total Non Current Assets |
|
2.19
|
| Net PPE |
|
2.19
|
| Gross PPE |
|
2.38
|
| Accumulated Depreciation |
|
-0.19
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.38
|
| Other Properties |
|
1.92
|
| Leases |
|
0.09
|
| Total Liabilities Net Minority Interest |
|
58.45
|
| Current Liabilities |
|
7.23
|
| Payables And Accrued Expenses |
|
5.97
|
| Payables |
|
3.98
|
| Accounts Payable |
|
3.98
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
1.99
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.71
|
| Current Debt And Capital Lease Obligation |
|
0.55
|
| Current Capital Lease Obligation |
|
0.55
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
51.23
|
| Long Term Debt And Capital Lease Obligation |
|
51.23
|
| Long Term Debt |
|
49.77
|
| Long Term Capital Lease Obligation |
|
1.46
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
16.77
|
| Common Stock Equity |
|
16.77
|
| Capital Stock |
|
260.50
|
| Common Stock |
|
260.50
|
| Share Issued |
|
33.48
|
| Ordinary Shares Number |
|
33.48
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
33.83
|
| Retained Earnings |
|
-326.03
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
| Total Equity Gross Minority Interest |
|
16.77
|
| Total Capitalization |
|
66.54
|
| Working Capital |
|
65.81
|
| Invested Capital |
|
66.54
|
| Total Debt |
|
51.77
|
| Net Debt |
|
36.01
|
| Capital Lease Obligations |
|
2.00
|
| Net Tangible Assets |
|
16.77
|
| Tangible Book Value |
|
16.77
|
| Foreign Currency Translation Adjustments |
|
—
|
| Other Equity Interest |
|
48.46
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-49.04
-70.00%
|
-28.85
+37.86%
|
-46.42
+11.52%
|
-52.47
|
| Cash Flow From Continuing Operating Activities |
|
-49.04
-70.00%
|
-28.85
+37.86%
|
-46.42
+11.52%
|
-52.47
|
| Net Income From Continuing Operations |
|
-63.06
-51.88%
|
-41.52
+30.44%
|
-59.69
-2.22%
|
-58.39
|
| Depreciation Amortization Depletion |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| Depreciation |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| Depreciation And Amortization |
|
0.11
+8.57%
|
0.10
+14.13%
|
0.09
+3.37%
|
0.09
|
| Other Non Cash Items |
|
3.84
+7.23%
|
3.58
+40.17%
|
2.55
|
—
|
| Stock Based Compensation |
|
7.46
+29.17%
|
5.78
-39.42%
|
9.53
+5.37%
|
9.05
|
| Operating Gains Losses |
|
—
|
0.01
|
—
|
0.14
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.01
|
0.00
-100.00%
|
0.14
|
| Change In Working Capital |
|
2.68
-26.59%
|
3.66
+194.13%
|
1.24
+138.11%
|
-3.26
|
| Change In Receivables |
|
-1.12
-176.51%
|
1.46
+155.34%
|
-2.64
-261.37%
|
-0.73
|
| Change In Inventory |
|
-0.65
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
0.03
-97.83%
|
1.34
-52.67%
|
2.83
+265.71%
|
-1.71
|
| Change In Payables And Accrued Expense |
|
4.43
+406.51%
|
0.88
-15.54%
|
1.04
+214.22%
|
-0.91
|
| Change In Other Working Capital |
|
-0.01
+29.41%
|
-0.02
-194.44%
|
0.02
-77.78%
|
0.08
|
| Investing Cash Flow |
|
11.25
+35.77%
|
8.28
+74.16%
|
4.76
+108.33%
|
-57.12
|
| Cash Flow From Continuing Investing Activities |
|
11.25
+35.77%
|
8.28
+74.16%
|
4.76
+108.33%
|
-57.12
|
| Net PPE Purchase And Sale |
|
-0.30
-815.15%
|
-0.03
+70.54%
|
-0.11
+58.82%
|
-0.27
|
| Purchase Of PPE |
|
-0.30
-815.15%
|
-0.03
+70.54%
|
-0.11
+58.82%
|
-0.27
|
| Capital Expenditure |
|
-0.30
-815.15%
|
-0.03
+70.54%
|
-0.11
+58.82%
|
-0.27
|
| Net Investment Purchase And Sale |
|
11.55
+38.86%
|
8.32
+70.83%
|
4.87
+108.56%
|
-56.85
|
| Purchase Of Investment |
|
-82.92
+26.98%
|
-113.55
+17.19%
|
-137.13
-59.73%
|
-85.85
|
| Sale Of Investment |
|
94.47
-22.49%
|
121.87
-14.18%
|
142.00
+389.66%
|
29.00
|
| Financing Cash Flow |
|
85.53
+166.28%
|
32.12
-32.79%
|
47.79
+1447.67%
|
3.09
|
| Cash Flow From Continuing Financing Activities |
|
85.53
+166.28%
|
32.12
-32.79%
|
47.79
+1447.67%
|
3.09
|
| Net Issuance Payments Of Debt |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
50.00
|
0.00
|
| Net Common Stock Issuance |
|
51.01
+87.13%
|
27.26
|
0.00
-100.00%
|
2.63
|
| Proceeds From Stock Option Exercised |
|
34.52
+610.10%
|
4.86
+746.86%
|
0.57
+25.33%
|
0.46
|
| Net Other Financing Charges |
|
—
|
—
|
-2.78
|
—
|
| Changes In Cash |
|
47.73
+313.12%
|
11.55
+88.67%
|
6.12
+105.75%
|
-106.50
|
| Beginning Cash Position |
|
25.31
+83.97%
|
13.76
+80.20%
|
7.64
-93.31%
|
114.14
|
| End Cash Position |
|
73.05
+188.56%
|
25.31
+83.97%
|
13.76
+80.20%
|
7.64
|
| Free Cash Flow |
|
-49.34
-70.85%
|
-28.88
+37.94%
|
-46.54
+11.77%
|
-52.74
|
| Amortization Of Securities |
|
-0.08
+82.16%
|
-0.45
-180.25%
|
-0.16
-67.01%
|
-0.10
|
| Common Stock Issuance |
|
51.01
+87.13%
|
27.26
|
0.00
-100.00%
|
2.63
|
| Issuance Of Capital Stock |
|
51.01
+87.13%
|
27.26
|
0.00
-100.00%
|
2.63
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-05-13 View
- 10-Q2026-05-13 View
- 42026-04-20 View
- 8-K2026-03-20 View
- 10-K2026-03-20 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-02-04 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 8-K2026-01-26 View
- 8-K2026-01-13 View
- 42026-01-09 View
- 8-K2026-01-06 View
- 8-K2025-12-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|